Upside – $IRON +52% (Phase 3 APOLLO trial met all primary and secondary endpoints in erythropoietic protoporphyria) – $AAME +41% (long-delayed 2025 annual report was filed, showing a return to annual profitability) – $XLAB +24% (extends rally after securing an $8.2M AI-server order) – $TCRT +20% (extends volatile rally tied to a proposed acquisition and …
Read in context ›Alaunos Therapeutics Stock (TCRT)
Track Alaunos Therapeutics stock through TheStreet Pro's latest coverage, including articles, Daily Diary mentions, TheStreet Pro portfolio activity, contributor watchlist signals, and Pro price levels.
TCRT
Alaunos Therapeutics
healthcare
At close
$1.62
â–² +0.01 (+0.62%)
Nov 12, 4:00 PM ET
Pre-market
$1.63
â–² +0.01 (+0.62%)
Nov 13, 6:10 AM ET
Market Cap
$6.65M
P/E Ratio
—
1Y Return
-45.82%
EPS (TTM)
-$1.95
Read the latest TheStreet Pro articles mentioning Alaunos Therapeutics, including market roundups, portfolio updates, trade ideas, and investing analysis.
Articles
0 articlesNo articles mentioning TCRT yet.
Daily Diary Mentions
3 mentionsSelect Upside, Downside Movers in the Morning Upside, Downside Movers in the Morning Upside – $TCRT +25.0% (extends its surge after closing a PAH-focused biotech acquisition and securing about $350M of financing) – $NCPL +19.0% (regains Nasdaq minimum-bid compliance) – $SITC +18.0% (declares a $3.00 special cash distribution after an asset sale and plans to delist from the NYSE) – $FFR +9.0% (launches the $2,490 FF Nova humanoid …
Read in context ›Select Premarket Movers Upside – $LQDA +41.0% ($380.7M global settlement resolves six lawsuits and preserves uninterrupted YUTREPIA commercialization) – $TCRT +25.5% (completed Velaris acquisition and secured an approximately $350M private placement to fund development through 2029) – $VSTM +11.0% (VS-7375 produced a 50% confirmed response rate in eight second-line pancreatic-cancer patients, with FDA alignment on a Phase 3 …
Read in context ›